secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELI LILLY & Co (LLY)
CIK:        0000059478
Form:       8-K
Filed at:   2021-08-17T23:59:59+00:00
Accession:  0000059478-21-000175
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lilly restructures leadership; Zulueta retiring, Yuffa to lead International, new Neuroscience & Immunology units
--------------------------------------------------------------------------------

- Alfonso Zulueta, President of Lilly International, to retire effective Dec 26, 2021; succeeded by Ilya Yuffa.
- Lilly Bio-Medicines splits into two units: Lilly Neuroscience (led by Anne White) and Lilly Immunology (led by Patrik Jonsson).
- Jake Van Naarden promoted to CEO of Loxo Oncology at Lilly and President of Lilly Oncology, joins executive committee.
- Donanemab (Alzheimer's) BLA submission planned under accelerated approval pathway; tirzepatide (type 2 diabetes) potential launch cited.
- Changes effective Sept 5, 2021; CEO David Ricks cites focus on late-stage pipeline and breakthrough medicines.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/59478/000005947821000175/0000059478-21-000175-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/59478/000005947821000175/lly-20210811.htm
  HTML page:      https://secwatch.observer/filing/0000059478-21-000175

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer